Future directions for vaccine discovery 2

Published on May 28, 2015   25 min

You are viewing a talk that is a part of one of our comprehensive courses. Additional learning material: case studies, projects, workshops and recommended reading; multiple choice questions and suggested exam questions with model answers are available on application. Learn more

Other Talks in the Series: Vaccines

Now, let me ask the question, can the same principles, somewhat complex, that I've just walk you through that we've used to create an HIV vaccine be applied to produce a vaccine to prevent the acquisition or transmission of sound falciparum malaria, the most virulent and lethal form of malaria. This disease is transmitted by the bite of mosquitoes that contain infectious parasites. The problem, then, is infection with Plasmodium falciparum, the proper name of the falciparum malaria parasite, can induce immunity to the red cell stage of the disease, reducing its severity. But that infection does not prevent infection or transmission. In other words, just like for HIV, we have to have a vaccine that is better than natural infection at inducing protection. That is, the challenge to prevent infection or transmission of the infection to others is that the vaccine must be more protective than natural infection. It must induce an unnatural form of immunity to relatively invariant pre red cells stages of the parasite, or stages of the parasite called gametocytes that are transmitted into other mosquitoes, and are then ultimately in that mosquito turned into new parasites that can affect another individual. And those antigens are not targets of natural immunity in infection.

Future directions for vaccine discovery 2

Embed in course/own notes